Introduction. The COVID-19 pandemic has severely affected patients with Irritable Bowel Syndrome (IBS), which has led to a change in the symptoms of BrainGut axis disease. Aim. The aim of this study was to evaluate the particularities of IBS symptoms in comorbid patients with COVID-19 positive. Material and methods. In the prospective study, 31 patients with IBS + COVID-19 positive were examined compared to 34 patients with IBS without infection, representing the control group (diagnosis was established according to ROME-IV criteria, as well as after exclusion Crohn’s disease, ulcerative colitis, CDI (Clostridium Difficile Infection) and colorectal cancer The mean age was 38 ± 2.1 years, the ratio of women to men was 4: 3 All patients underwent fibrocolonoscopy (FCS) with biopsy , Stool Ag-Hp test, quantitative / qualitative calprotectin, onco-markers (CEA, CA-19.9, CA-153, CA-125). Symptoms of IBS were assessed at the beginning and end of COVID-19 acute and symptomatic COVID-19 infection in progress (according to NICE division). Results. Division according to ROMA IV criteria highlighted: IBS-constipation - 7 patients (22.6%), IBS-mixed - 12 patients (38.7%), IBS-diarrhea - 9 patients (29%), IBS-unclassified - 3 patients (9.7%). Of patients with positive SII + COVID-19 (58.1%) reported a deterioration of symptoms: diarrhea and mixed symptoms (alternating constipation / diarrhea), as well as pain syndrome. SII predominantly with diarrhea was positively associated with COVID-19. In the control group IBS patients stated that their symptoms remained unchanged. Conclusions. Patients with IBS comorbid with SARS CoV-2 infection have been adversely affected by the COVID-19 pandemic, which should be considered at the developmental stage and in the unspecified post-COVID syndrome.